{
  "id": 651849,
  "title": "First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial",
  "url": "https://urgent.news/2026/08/12/first-line-pd-1-vegf-bispecific-antibody-plus-chemotherapy-in-triple",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-12T00:00:00.000Z",
  "source": {
    "name": "Nature Medicine",
    "slug": "nature-medicine",
    "url": "https://www.nature.com/articles/s41591-026-04564-7"
  },
  "original_language": "en",
  "account": null,
  "summary": "Nature Medicine, Published online: 12 August 2026; doi:10.1038/s41591-026-04564-7 In a multicenter, phase 2 trial, patients with treatment-naive locally advanced unresectable or metastatic triple-negative breast cancer were treated with the PD-1/vascular endothelial growth factor bispecific antibody ivonescimab plus chemotherapy, resulting in encouraging preliminary objective response rates,…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}